Skip to main content
IFRX
NASDAQ Life Sciences

InflaRx Secures $140M in Offering, Extends Cash Runway to 2029, and Pursues Expanded AAV Strategy

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.74
Mkt Cap
$260.708M
52W Low
$0.741
52W High
$2.949
52W Position info
135% above low
Off High info
41% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

IFRX has more than doubled off its 52-week low of $0.741 on light trading volume (0.4× avg).

Summary

InflaRx reported Q2 2026 financial results, highlighting a successful $140.4 million underwritten offering in May that extends its cash runway through 2029, alongside a strategic reassessment of its ANCA-associated vasculitis (AAV) development in Europe.


Key Events · Financing and Capital Events · IFRX

  • Significant Capital Raise Completed

    InflaRx completed an underwritten registered direct offering in May 2026, issuing 75,000,000 ordinary shares at $2.00 per share, generating net proceeds of €119.3 million ($140.4 million).

  • Cash Runway Extended to 2029

    The proceeds from the offering, combined with existing funds, provide a projected cash runway through the end of 2029, significantly de-risking near-term operations.

  • Reduced Net Loss in H1 2026

    The company reported a net loss of €16.2 million for the first half of 2026, an improvement from €22.7 million in the same period of 2025, reflecting cost control after discontinuing US sales activities.

  • Strategic AAV Opportunity in Europe

    InflaRx is assessing a broadened development and registrational strategy for izicopan and vilobelimab in European ANCA-associated vasculitis (AAV), following the EMA's recommendation to revoke a competitor's marketing authorization.


Analysis · IFRX · Life Sciences

This filing confirms InflaRx's strengthened financial position following a substantial $140.4 million capital raise in May, which has extended its cash runway through 2029. This significantly reduces financial uncertainty for the company. Concurrently, InflaRx is strategically positioned to capitalize on a shifting competitive landscape in ANCA-associated vasculitis (AAV) in Europe, with plans to engage the EMA regarding its drug candidates after a competitor's marketing authorization was recommended for revocation. Progress in izicopan's development, including new preclinical data and a planned PK bridging study in China, further supports its pipeline.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IFRX was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $260.7M. The 52-week trading range was $0.74 to $2.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IFRX - Latest Insights

IFRX
Nov 03, 2026, 4:34 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $1.17 info
Change: -$0.4152 (-26%) info
Market Cap: $171.684M info
IFRX
Nov 03, 2026, 8:12 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.66
Real-time Price: $1.17 info
Change: -$0.495 (-30%) info
Market Cap: $171.684M info
IFRX
Jun 30, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.24
Real-time Price: $1.17 info
Change: -$1.08 (-48%) info
Market Cap: $171.684M info
IFRX
Jun 30, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.26
Real-time Price: $1.17 info
Change: -$1.09 (-48%) info
Market Cap: $171.684M info
IFRX
May 07, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.66
Real-time Price: $1.17 info
Change: -$1.50 (-56%) info
Market Cap: $171.684M info